top of page

NASH Companies Back in the Spotlight!

Updated: Dec 16, 2022

(First posted 12/15/22)


  • NASH is a liver disease that is one of the most challenging diseases for finding effective therapeutics. There still are no approved drugs to treat NASH after years and billions of dollars of research.

  • NASH was a high flying indication for biopharma company valuations and investors around 5 years ago when many companies entered the space.

  • See Table 1 for smid-cap biopharmas that currently have NASH assets. Included is info on trial stage, mechanism of action (MoA), targets, and hedge funds holding each company.

  • Sign up for free to see our forum post with even more info on these NASH companies and readouts!

 

Sign up to get the full report for free!

 


Table 1. Smid-cap biopharmas with NASH trials.



Sign up for free to see our forum post with even more info on these NASH companies and readouts!

 

If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.


Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!


 

See what our members are saying about us:


Mike from United States

“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”

Carl from United States

“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”

Essey from Canada

“Love what you’re doing, this website is awesome.”

James from United States

Great site and I see it’s a family run business, great job.”

0 comments
bottom of page